CLINICAL ROLE -
Key Takeaways on FMTs in the Treatment of CDI
Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.
Economic Implications of FMTs on CDI
Joseph Reilly, BS, PharmD, BCGP, reviews the positive economic impact of use of live-jslm for treatment of CDI in a hospital setting.
Preventing the Spread of CDI in the Healthcare Setting
Experts comment on the measures that need to be taken to prevent or control the spread of CDI in the healthcare setting.
Clinical Overview: Steps to Implementation of Rebyota for Recurrent C difficile Infection
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.
Clinician and Patient Education on FMT in CDI
Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.
Insurance Coverage of FMTs in CDI
Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.
Incorporating FMT Treatment Into Clinical Practice
Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.
Advances in the CDI Treatment Landscape
Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.
Use of Live-JSLM in the Treatment of CDI
Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.
Use of Fecal Microbiota Transplantation (FMT) Treatment in CDI
Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.
Challenges in the Management of CDI
Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.
Diagnosis of C difficile Infection (CDI)
Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.
Overview of Gut Microbiome
Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.
Unrecognized Costs Associated With Clostridium Difficile Infection: What HCPs Often Miss
From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.
2 Clarke Drive Cranbury, NJ 08512